Pluripotent and Multipotent Stem Cells and Current Therapeutic Applications: Review

Worku, Misganaw Gebrie

doi:10.2147/sccaa.s304887

Cited by 10 publications

(8 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…So far, stem cell therapy has become a new hope for the treatment of many incurable diseases, but still faces problems such as low engraftment rate, limited efficacy, tumor formation, storage, and transportation [ [184] , [185] , [186] , [187] ]. Moreover, the sources of stem cells are very limited, and the acquisition process often causes great damage or adverse effects on the psychological and physiological conditions of recipients and donors [ 188 ].…”

Section: Discussionmentioning

confidence: 99%

Research progress of stem cell therapy for endometrial injury

Cen¹,

Zhang²,

Bai³

et al. 2022

Materials Today Bio

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Research progress of stem cell therapy for endometrial injury

Cen¹,

Zhang²,

Bai³

et al. 2022

Materials Today Bio

View full text Add to dashboard Cite

“…To execute their specialized maintenance and repair functions, HSCs give rise to descendants known as hematopoietic progenitor cells (HPCs), which can either self-renew or further differentiate into specific blood cells [22]. HSCs inhabit a highly regulated environment, often termed "the niche", referring to the microenvironment in which the cells reside [186]. The niche dictates signaling to HSCs that then decide when the cells should proliferate, self-renew, differentiate, or migrate [186].…”

Section: Understanding Hematopoiesis For Interpreting Hematotoxicitymentioning

confidence: 99%

“…HSCs inhabit a highly regulated environment, often termed "the niche", referring to the microenvironment in which the cells reside [186]. The niche dictates signaling to HSCs that then decide when the cells should proliferate, self-renew, differentiate, or migrate [186]. Niche regulatory signals vary in their forms, including cell-bound or secreted factors, in addition to cues from other HSCs or nonhematopoietic cell types, including mesenchymal and endothelial stem cells.…”

Section: Understanding Hematopoiesis For Interpreting Hematotoxicitymentioning

confidence: 99%

Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective

Ali

Raj

Kaur

et al. 2022

Cancers

View full text Add to dashboard Cite

Anticancer nucleoside analogs produce adverse, and at times, dose-limiting hematological toxicities that can compromise treatment efficacy, yet the mechanisms of such toxicities are poorly understood. Recently, cellular nucleoside transport has been implicated in normal blood cell formation with studies from nucleoside transporter-deficient mice providing additional insights into the regulation of mammalian hematopoiesis. Furthermore, several idiopathic human genetic disorders have revealed nucleoside transport as an important component of mammalian hematopoiesis because mutations in individual nucleoside transporter genes are linked to various hematological abnormalities, including anemia. Here, we review recent developments in nucleoside transporters, including their transport characteristics, their role in the regulation of hematopoiesis, and their potential involvement in the occurrence of adverse hematological side effects due to nucleoside drug treatment. Furthermore, we discuss the putative mechanisms by which aberrant nucleoside transport may contribute to hematological abnormalities and identify the knowledge gaps where future research may positively impact treatment outcomes for patients undergoing various nucleoside analog therapies.

show abstract

“…There are high hopes for the use of MSCs derived from the umbilical cord, among others, in the treatment of ischemic stroke or myocardial damage. [11][12][13] However, there is still a lack of studies evaluating how clinical parameters related to the course of pregnancy and delivery affect the secretory properties of mesenchymal stem cells of the umbilical cord.…”

Section: Introductionmentioning

confidence: 99%

VEGF Expression in Umbilical Cord MSC Depends on the Patient’s Health, the Week of Pregnancy in Which the Delivery Took Place, and the Body Weight of the Newborn – Preliminary Report

Bieńko¹,

Wójcik²,

Więckowska³

et al. 2023

SCCAA

View full text Add to dashboard Cite

Introduction: Cells collected from Wharton's jelly are a rich source of mesenchymal stem cells. They can be easily obtained and grown using the adhesive method. They produce many types of proteins, including VEGF. Their role is to participate in angiogenesis, vasodilation, stimulation of cells to migrate, and chemotactic activity. The aim of this study was to evaluate expression of genes from the vascular endothelial growth factor family: VEGFA, VEGFB and VEGFC in MSC and the analysis of dependence of the expression of the studied genes on clinical factors related to the course of pregnancy and childbirth, and health of mother and child. Material and Methods: The research material was an umbilical cord obtained from 40 patients hospitalized in the Department of Obstetrics and Pathology of Pregnancy of the Independent Public Clinical Hospital No.1 in Lublin. The age of the women was 21-46, all gave birth by cesarean section. Some of the patients suffered from hypertension and hypothyroidism. Material collected from patients immediately after delivery was subjected to enzymatic digestion with type I collagenase. The isolated cells were then cultured in adherent conditions, and then gene expression was assessed using qPCR and the immunophenotype of the cells was assessed cytometrically.Results: Conducted studies have shown significant differences in expression of VEGF family genes depending on clinical condition of mother and child. Significant differences in VEGF-family gene expression level in umbilical cord MSC collected from women with hypothyroidism, hypertension, time of labor and birth weight of the baby were shown. Conclusion:Probably due to hypoxia (caused, for example, by hypothyroidism or hypertension), the MSCs found in the umbilical cord may react with an increased expression of VEGF and a compensatory increase in the amount of secreted factor, the aim of which is, i.a., vasodilation and increase of blood supply to the fetus through the umbilical vessels.

show abstract

Pluripotent and Multipotent Stem Cells and Current Therapeutic Applications: Review

Cited by 10 publications

References 53 publications

Research progress of stem cell therapy for endometrial injury

Research progress of stem cell therapy for endometrial injury

Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective

VEGF Expression in Umbilical Cord MSC Depends on the Patient’s Health, the Week of Pregnancy in Which the Delivery Took Place, and the Body Weight of the Newborn – Preliminary Report

Contact Info

Product

Resources

About